BISHOP, Calif., Oct. 12, 2018 /PRNewswire-PRWeb/ -- David Young was the inventor of US National Defense Stealth Technology
The Two-Dimensional Arrhythmia Monitor has the potential to reduce some of the 350,000 lives lost to SCD annually. Targeted Heart Health patients: Asymptomatic Elderly with AF-Arrhythmia.
David W. Young had a stroke in 2012, followed by continuous AF-arrhythmia, and was therefore forced to develop and patent, self-control processes, in order to survive.
The patient can become visually familiar with their persistent AF-Arrhythmia, throughout the day. Using this simple two dimensional, pulse-to-pulse (RR) heart rate monitor, you can view a moving 60 second window in real-time, featuring graphical and aural display. David found his own SCD seemed to have been avoided 5 times by ceasing activity, when his arrhythmia spread in seconds from a controlled 60-90 bpm to an out-of-control 60-140 bpm or more. Mr. Young was able to bring down the rhythm spread with concentrated, calming, resonant-breathing of 10 second periods or adding the tiny amount of 40 MG of the antiarrhythmic, Sotalola, or as needed.
Real-time Poincaré Scatter plots Understanding Atrial Fibrillation page 113 have also been developed for on the spot arrhythmia risk evaluation. Other display-devices may be used with enough educated experience. New Apple Watch: The Worst Heart Device Ever?.
Patent TITLE: ARRHYTHMIA DISPLAYED SELF-AWARE LIFE-STYLE PROCESSES For SCD Prevention, specifically within the 24 hours of the observers "last known well," by evaluating controlled AF 60-100 bpm, assuring SiO2: 95-100% using real-time, pulse-to-pulse displays of heart-rate and/or hearing each Arrhythmia pulse converted to linearly scaled Musical Pitched Notes. Pitch increases with increasing heart rate. As arrhythmia complexity increases, SpO2 increases are measured in 1% increments and displayed audibly & visually. Sudden Cardiac Death: A Race for Time
The DWY Laboratory has many modern, technical, heart monitoring devices and related displays including many modernized ECGs and at least 75 current arrhythmia reference articles to share. Daily priority activity is staying alive, without unusual stress. One of the heart rate monitor straps, with snapped on sensor, is selected daily for a real-time, beat-to-beat mobile monitor display, or displays if presentations are to be compared. The Two-Dimensional Arrhythmia Display (2DAM) has the advantage over the Karia AliveCor Mobile Watch in that the 2DAM displays real-time, graphical and audio heart performance instead of just detecting atrial fibrillation and only displaying heart rate numbers. Emphasis in 2DAM is placed on active arrythmia control. The 2DAM display standard has no averaging, i.e. every-pulse-counts. (Sometimes averaging is employed for instruments having a 3-pulse averaging specifically for some clinical stress test comparisons.) As Mr. Young's age increased to age 90, he found his heart rate variability diminished from a 12 bpm spread to zero spread. Mr. Young had a resting pulse of 66 bpm on April 21, 2014 to zero heart rate variability (HRV) instead of 12 bpm variability, from 2016 to today. Sometimes Mr. Young's arrhythmia is constant, sinus, the HRV being zero for that short period of time with but a few premature atrial contractions (PACs).
David has worked with microwaves much of his life with 26 patents, but now he has been required to evaluate his own heart waves to survive. This measure is not something that can necessarily be done by a doctor -- only by the patient experiencing the arrhythmia at the moment. This is not screening. The patient must make the measurements, near the time when the arrhythmia is suddenly characterized by the "accelerated, chaotic and uncoordinated atrial activation and contraction" to act and prevent further risk of escalation. Understanding Atrial Fibrillation: The Signal Processing Contribution, Part I
Self-Monitoring has been shown to be of value even if the monitoring was not used for change in behavior. But changing behavior has been shown to provide AF-Arrhythmia Control of Sudden Cardiac Death [SCD]. The restricted but valued monitoring was provided with a Grant from ICD manufacturer, Medtronic. Monitoring Patients With Implantable Cardioverter Defibrillators Using Mobile Phone Electrocardiogram: Case Study
The invented algorithm is available for informal personal use or corporate lease.
The DWY Laboratory offers a patent-pending [fast-track, age 90] lease. The initial cost is zero and then the price is increased depending on performance-value. Applicants must have a group member with nearly constant AF-arrhythmia that features calm resting values of 60-90 bpm spread over a 1-minute distribution of pulse-to-pulse heart rate to qualify.
Qualified individuals, having substantial AF-arrhythmia, may use the press contact email for informal patent-process briefing details.
The descriptions above are of David Young's personal experience. None of the above should be considered expert medical advice. You should consult your own doctor.
SOURCE David Young
Subscribe to our Free Newsletters!